Clinigen adds U.S. rights to Proleukin

Clinigen Group plc (LSE:CLIN) jumped 134.5p (18%) to 872p on Wednesday after the U.K. specialty pharma said it will acquire U.S. rights

Read the full 227 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE